These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29135116)

  • 1. Serum S100B levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH.
    Karonidis A; Mantzourani M; Gogas H; Tsoutsos D
    J BUON; 2017; 22(5):1296-1302. PubMed ID: 29135116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
    de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
    Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
    Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
    Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
    Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status.
    Frauchiger AL; Mangana J; Rechsteiner M; Moch H; Seifert B; Braun RP; Dummer R; Goldinger SM
    Br J Dermatol; 2016 Apr; 174(4):823-30. PubMed ID: 26659191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma.
    Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
    Oncology; 1999; 56(4):338-44. PubMed ID: 10343200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
    Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
    Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
    Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
    Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
    Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
    Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
    Wagner NB; Forschner A; Leiter U; Garbe C; Eigentler TK
    Br J Cancer; 2018 Aug; 119(3):339-346. PubMed ID: 29950611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
    Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
    Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors.
    Gassenmaier M; Lenders MM; Forschner A; Leiter U; Weide B; Garbe C; Eigentler TK; Wagner NB
    Target Oncol; 2021 Mar; 16(2):197-205. PubMed ID: 33555543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker.
    Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
    Melanoma Res; 2003 Dec; 13(6):587-93. PubMed ID: 14646622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma.
    Polivka J; Gouda MA; Sharif M; Pesta M; Huang H; Treskova I; Woznica V; Windrichova J; Houfkova K; Kucera R; Fikrle T; Ricar J; Pivovarcikova K; Topolcan O; Janku F
    Cancer Med; 2024 Oct; 13(19):e70313. PubMed ID: 39387479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
    Weide B; Elsässer M; Büttner P; Pflugfelder A; Leiter U; Eigentler TK; Bauer J; Witte M; Meier F; Garbe C
    Br J Cancer; 2012 Jul; 107(3):422-8. PubMed ID: 22782342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconsidering S100B: Why it is time to abandon its use in detecting disease recurrence in stage III melanoma patients.
    Jansen MR; Caini S; Stanganelli I; Been LB; van Leeuwen BL
    Eur J Surg Oncol; 2024 Jul; 50(7):108442. PubMed ID: 38820924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
    Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
    Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients.
    Gebhardt C; Lichtenberger R; Utikal J
    J Dtsch Dermatol Ges; 2016 Feb; 14(2):158-64. PubMed ID: 26819111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.